Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70483 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Daniele Avenoso und 21 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili d…. Hauptthemen laut MEDLINE: Busulfan, Leukemia, Myeloid, Acute, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative strategy for acute myeloid leukemia (AML), but the impact of HLA disparity in the era of posttransplant cyclophosphamide (PTCy) and reduced‐toxicity conditioning remains unclear. We performed an EBMT registry study including 275 adult AML patients in first complete remission undergoing first allo‐HSCT between 2012 and 2023 using a uniform platform of treosulfan‐based conditioning and PTCy. Among them, 206 received haploidentical grafts and 69 underwent 9/10 mismatched unrelated donor (MMUD) transplantation. Median follow‐up was 2.5 years. At 2 years, overall survival was 73.1% after haploidentical transplantation and 71.6% after MMUD transplantation ( p = 0.96). Leukemia‐free survival at 1 year was 66.3% and 65.2%, respectively ( p = 0.76). Relapse incidence (17.1% vs. 18.7%, p = 0.84) and nonrelapse mortality (16.6% vs. 16.1%, p = 0.86) were comparable between groups. Rates of Grade II–IV and Grade III–IV acute GVHD were similar, whereas chronic GVHD was higher after haploidentical transplantation (36.4% vs. 12.7%, p = 0.001), without differences in extensive forms. In multivariable analyses, donor type was not associated with overall survival, leukemia‐free survival, relapse incidence, or nonrelapse mortality. Increasing age adversely affected outcomes, while Karnofsky performance status ≥ 90 and reduced‐intensity conditioning were associated with improved survival. These findings suggest that, within a treosulfan–PTCy platform, major transplant outcomes are comparable between donor types, although haploidentical transplantation was associated with a higher incidence of chronic GVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
- Service D'hematologie, Departement d'Oncologie, and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- BMT Unit, Hematology Division, Fondazione IRCCS-Ca' Granda OMP, Milano, Italy.
- Haematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Oncohematology Division, European Institute of Oncology, IRCCS, Milan, Italy.
- Department of Health Sciences, University of Milan, Milan, Italy.
ORCID-Profile: Daniele Avenoso, Mirko Farina, Michele Malagola, Yves Chalandon, Enrico Derenzini, Peter Remenyi, Massimo Martino, Didier Blaise, Desiree Kunadt, Franca Fagioli, Eolia Brissot, Fabio Ciceri
Zitieren
APA
Avenoso, D., Farina, M., Malagola, M., Chalandon, Y., Saporiti, G., Imovilli, A., Derenzini, E., Remenyi, P., Martino, M., Itala-Remes, M., Fanin, R., Blaise, D., Kunadt, D., Rodriguez, A. B., Fagioli, F., Schroeder, T., Cavattoni, I., Ngoya, M., Houhou, M., …, & Ciceri, F. (2026). Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy. American Journal of Hematology. https://doi.org/10.1002/ajh.70483
Vancouver
Avenoso D, Farina M, Malagola M, Chalandon Y, Saporiti G, Imovilli A, et al. Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy. American Journal of Hematology. 2026. doi:10.1002/ajh.70483
BibTeX
@article{Avenoso2026,
author = {Avenoso, Daniele and Farina, Mirko and Malagola, Michele and Chalandon, Yves and Saporiti, Giorgia and Imovilli, Annalisa and Derenzini, Enrico and Remenyi, Peter and Martino, Massimo and Itala-Remes, Maija and Fanin, Renato and Blaise, Didier and Kunadt, Desiree and Rodriguez, Arancha Bermudez and Fagioli, Franca and Schroeder, Thomas and Cavattoni, Irene and Ngoya, Maud and Houhou, Mohamed and Mohty, Mohamad and Brissot, Eolia and Ciceri, Fabio},
title = {Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70483}
}
EUVIMED